{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:33:10Z","timestamp":1788910390692,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12325-022-02384-y","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T06:02:43Z","timestamp":1671170563000},"page":"2710-2724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-557X","authenticated-orcid":false,"given":"Juan","family":"Cosin-Sales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Sidelnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Villamayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Merino-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"25","key":"2384_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"2384_CR2","first-page":"1","volume":"9","author":"N Townsend","year":"2021","unstructured":"Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2021;9:1\u201311.","journal-title":"Nat Rev Cardiol"},{"key":"2384_CR3","unstructured":"INE. Instituto Nacional de Estad\u00edstica. https:\/\/www.ine.es\/dyngs\/INEbase\/listaoperaciones.htm. Accessed Jan 2022."},{"issue":"1","key":"2384_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1186\/1471-2458-10-627","volume":"10","author":"A Rubinstein","year":"2010","unstructured":"Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10(1):627.","journal-title":"BMC Public Health"},{"key":"2384_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.recesp.2018.01.004","volume":"71","author":"J Pedro-Botet","year":"2018","unstructured":"Pedro-Botet J, Rodr\u00edguez-Padial L, Brotons C, Esteban-Sal\u00e1n M, Garc\u00eda-Ler\u00edn A, Pint\u00f3 X, et al. The ideal lipid report: a need for consensus. Rev Esp Cardiol (Engl Ed).\n2018;71:512\u20134.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"2384_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-020-01792-7","volume":"18","author":"PE Penson","year":"2020","unstructured":"Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer\u2014even at low risk. BMC Med. 2020;18(1):1\u20136.","journal-title":"BMC Med"},{"issue":"Suppl 2","key":"2384_CR7","first-page":"16","volume":"31","author":"J Pedro-Botet","year":"2019","unstructured":"Pedro-Botet J, Pint\u00f3 X. LDL-cholesterol: the lower the better. Clin Investig Arterioscler. 2019;31(Suppl 2):16\u201327.","journal-title":"Clin Investig Arterioscler"},{"issue":"32","key":"2384_CR8","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"16","key":"2384_CR9","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"J Hsia","year":"2011","unstructured":"Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol< 50 mg\/dl with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"2384_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"key":"2384_CR11","doi-asserted-by":"publisher","unstructured":"Puche JE, Mialdea D, V\u00e1zquez R. LDL-C levels in secondary prevention: the lower the better and the sooner the better. J Cardiol Cardiovasc Ther. 2021. https:\/\/doi.org\/10.19080\/JOCCT.2021.17.555954.","DOI":"10.19080\/JOCCT.2021.17.555954"},{"key":"2384_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab718","author":"KK Ray","year":"2021","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"key":"2384_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pcad.2020.12.008","volume":"67","author":"B Cybulska","year":"2021","unstructured":"Cybulska B, K\u0142osiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis. 2021;67:65\u201374.","journal-title":"Prog Cardiovasc Dis"},{"issue":"11","key":"2384_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239752","volume":"15","author":"AM Small","year":"2020","unstructured":"Small AM, Huffman JE, Klarin D, et al. PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. PLoS ONE. 2020;15(11):e0239752.","journal-title":"PLoS ONE"},{"issue":"18","key":"2384_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","volume":"75","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75(18):2283\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2384_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-Wi de cross-section al observational study of lipid-modifying therapy use in secondary and primary care: the DAVINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"2384_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","volume":"64","author":"JR Gonzalez-Juanatey","year":"2011","unstructured":"Gonzalez-Juanatey JR, Mill\u00e1n J, Alegr\u00eda E, Guijarro C, Lozano JV, Vitale GC. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study. Rev Esp Cardiol. 2011;64(4):286\u201394.","journal-title":"Rev Esp Cardiol"},{"key":"2384_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE\u00a0V survey in 27 countries. Atherosclerosis. 2019;285:135\u201346.","journal-title":"Atherosclerosis"},{"key":"2384_CR19","first-page":"19","volume":"24","author":"R Alonso","year":"2017","unstructured":"Alonso R, Cuevas A. Indicaciones para el uso de los inhibidores de la PCSK9. Rev Colomb Cardiol. 2017;24:19\u201324.","journal-title":"Rev Colomb Cardiol"},{"issue":"4","key":"2384_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","volume":"64","author":"JR Gonz\u00e1lez-Juanatey","year":"2011","unstructured":"Gonz\u00e1lez-Juanatey JR, Mill\u00e1n J, Alegr\u00eda E, Guijarro C, Lozano JV, Vitale GC. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain DYSIS-Spain Study. Rev Esp Cardiol. 2011;64(4):286\u201394.","journal-title":"Rev Esp Cardiol"},{"issue":"4","key":"2384_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archinte.160.4.459","volume":"160","author":"TA Pearson","year":"2000","unstructured":"Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459\u201367.","journal-title":"Arch Intern Med"},{"key":"2384_CR22","unstructured":"IPT. Informes de Posicionamiento Terap\u00e9utico. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ministerio de Sanidad. Gobierno de Espa\u00f1a. https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/informes-de-posicionamiento-terapeutico\/. Accessed Feb 2022."},{"issue":"6","key":"2384_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.recesp.2018.11.017","volume":"72","author":"A Cordero","year":"2019","unstructured":"Cordero A, F\u00e1cila L, Galve E, Juanatey JRG. Estimated percentage of patients with stable coronary heart disease candidates for PCSK9 inhibitors. Rev Esp Cardiol (Engl Ed). 2019;72(6):518\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"6","key":"2384_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.recesp.2018.12.012","volume":"72","author":"A Zamora","year":"2019","unstructured":"Zamora A, Masana L, Plana N, Ramos R. Estimated percentage of patients with stable coronary heart disease candidates for pcsk9 inhibitors. Response. Rev Esp Cardiol (Engl Ed). 2019;72(6):519\u201320.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"2384_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.recesp.2019.07.024","volume":"73","author":"C Escobar","year":"2020","unstructured":"Escobar C, Anguita M, Arrarte V, et al. Recomendaciones para mejorar el control lip\u00eddico. Documento de consenso de la Sociedad Espa\u00f1ola de Cardiolog\u00eda. Rev Esp Cardiol. 2020;73(2):161\u20137.","journal-title":"Rev Esp Cardiol"},{"issue":"29","key":"2384_CR26","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J"},{"issue":"1","key":"2384_CR27","first-page":"10","volume":"34","author":"C Guijarro","year":"2022","unstructured":"Guijarro C, Civeira F, L\u00f3pez-Miranda J, et al. Situaci\u00f3n en 2020 de los requerimientos para la utilizaci\u00f3n de inhibidores de PCSK9 en Espa\u00f1a: resultados de una encuesta nacional. Clin Investig Arterioscler. 2022;34(1):10\u20138.","journal-title":"Clin Investig Arterioscler"},{"key":"2384_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2022.06.154","volume":"355","author":"J Brandts","year":"2022","unstructured":"Brandts J, Bray S, Villa G, et al. LDL-cholesterol goal attainment through optimal implementation of the 2019 ESC\/EAS dyslipidemia treatment algorithm in European patients with\/without atherosclerotic cardiovascular disease: simulation study from DA VINCI. Atherosclerosis. 2022;355:23\u20134.","journal-title":"Atherosclerosis"},{"key":"2384_CR29","doi-asserted-by":"crossref","unstructured":"Ray KK, Dhalwani N, Sibartie M, et al. Low density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J Qual Care Clin Outcomes. 2022;8:447\u201346.","DOI":"10.1093\/ehjqcco\/qcac009"},{"issue":"12","key":"2384_CR30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.recesp.2017.11.006","volume":"71","author":"A Zamora","year":"2018","unstructured":"Zamora A, Masana L, Comas-Cufi M, et al. Number of patients eligible for PCSK9 inhibitors based on real-world data from 2.5 million patients. Rev Esp Cardiol (Engl Ed). 2018;71(12):1010\u20137.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2384_CR31","doi-asserted-by":"crossref","unstructured":"Anguita S\u00e1nchez M, G\u00f3mez Doblas JJ, Barrios Alonso V. Control of LDL-C levels after an acute coronary syndrome in Spain. Are the available treatments adequately used? Rev Esp Cardiol (Engl Ed). 2021;74(2):194\u20136.","DOI":"10.1016\/j.rec.2020.06.027"},{"issue":"3","key":"2384_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2384_CR33","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1503\/cmaj.070675","volume":"178","author":"K Josan","year":"2008","unstructured":"Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178(5):576\u201384.","journal-title":"CMAJ"},{"issue":"7","key":"2384_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.amjcard.2007.04.053","volume":"100","author":"SA Murphy","year":"2007","unstructured":"Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007;100(7):1047\u201351.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2384_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijcard.2011.10.128","volume":"166","author":"RA Ribeiro","year":"2013","unstructured":"Ribeiro RA, Ziegelmann PK, Duncan BB, et al. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. Int J Cardiol. 2013;166(2):431\u20139.","journal-title":"Int J Cardiol"},{"key":"2384_CR36","unstructured":"Grupo de Trabajo de la Sociedad Europea de Cardiolog\u00eda (ESC) de diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica Desarrollada con la colaboraci\u00f3n especial de la Heart Failure Association (HFA) de la ESC. Gu\u00eda ESC 2016 sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica. Rev Esp Cardiol. 2016;69(12):1167.e1\u2013.e85."},{"issue":"3","key":"2384_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","volume":"4","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206\u201313.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2384_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-019-1032-4","volume":"19","author":"S-T Chen","year":"2019","unstructured":"Chen S-T, Huang S-T, Shau W-Y, et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19(1):1\u201313.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02384-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:29:18Z","timestamp":1685075358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02384-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2384"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02384-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"18 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed graphical abstract was retrospectively added to this publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}